ArticleScientific reports2024
Exploring the dark side of diagnostic dyes with a focus on Indocyanine green's adverse reactions.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety of indocyanine green for lymph node mapping in early-stage vulvar cancer: multicenter evaluation and systematic review.Archives of gynecology and obstetrics · 2026Pooled it
- Quantification and mitigation of system background fluorescence in fiber-optic-based imaging systems.Biomedical optics express · 2026Article
- The Diagnostic Value of Indocyanine Green in the Assessment of Depth of Burn Injuries: A Systematic Review.European burn journal · 2026Review
- Indocyanine-Green-Guided Partial Nephrectomy: A Narrative Review Addressing Protocol Heterogeneity, Perioperative Functional and Oncological Outcomes.Medicina (Kaunas, Lithuania) · 2026Review
- Real-time bowel perfusion monitoring with FUJIFILM ELUXEO® VISION endoscopic imaging system in colorectal surgery.Surgical endoscopy · 2026Article
- Ureteral stricture: current treatment algorithm and key surgical principles in the robotic upper urinary tract reconstruction era.World journal of urology · 2026Review
- First Reported Case of Acute Kidney Injury Following Intraureteral Indocyanine Green Administration During Bilateral Endometrioma Excision.Journal of clinical medicine · 2025Article
- Real-time image-guided and computer augmented reality in minimally invasive hepatopancreatobiliary surgery cutting edge technology transforming HPB surgery.Surgical endoscopy · 2025Review
- Economic Evaluation and Budget Impact Analysis of Indocyanine Green Test for Preoperative Liver Function in Patients with Major Hepatectomy in Thailand.Advances in therapy · 2025Article
- Short-interval intravenous indocyanine green administration in pediatric laparoscopic cholecystectomy: a prospective evaluation of visualization and safety.Pediatric surgery international · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Indocyanine green (ICG) is a diagnostic dye commonly used in medical imaging and liver function monitoring. Given its widespread use, there is a need for detailed evaluations of its adverse drug reactions in real-world settings. As the comprehensive overview of its safety profile is very limited, this study aimed to analyze the adverse events (AEs) associated with ICG using data from the Food and Drug Administration Adverse Event Reporting System (FAERS). Data between 2004Q1 and 2023Q4 were extracted from the FAERS database. Signal detection was performed using various disproportionality analysis algorithms, including reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network, and multiitem gamma Poisson shrinker. During the study period, a total of 62 ICG-related AEs were reported in the FAERS database. Significant clinical adverse reactions included anaphylactic shock (ROR: 92.10, 95% confidence interval (CI): 37.71-224.96), procedural hypotension (ROR: 1397.27, 95% CI: 443.31-4404.08), and urticaria (ROR: 10.88, 95% CI: 4.02-29.42). This study provides valuable insights into the safety profile of ICG, highlighting the need for further monitoring to ensure its safe clinical use in clinical practice. Ongoing pharmacovigilance and large-scale studies are warranted to fully understand the potential risks associated with ICG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.